Exelixis (EXEL) Tops Q3 EPS by 8c; Comments on Outlook
More News related to BMY
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
- Asterand Announces Extension of Agreement with Bristol-Myers Squibb
- U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
- Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
More News related to EXEL
- Exelixis Announces December 1 Webcast of Presentation at Piper Jaffray's 21st Annual Healthcare Conference
- Exelixis Announces Webcast of Its Fifth Annual R&D Day on December 2
- Unusual 11 Mid-Day Movers 11/18: ABK, LZB, NLST, LDK Higher; ONCY, NANO, EXEL, VRUS Lower
- Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference
- Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
More News related to SNY
- New GoMeals(TM) iPhone Application from sanofi-aventis U.S. to Help People with Diabetes Eat Healthy Anywhere, Anytime
- VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
- Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc.
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
- Notable Analyst Rating Changes 11/16: COH, JWN, GNK, ESEA, SVA, YGE Upgraded; PARD, GPS, JCP, DLTR Downgraded
Exelixis (NASDAQ: EXEL) reports a Q3 loss of $0.24, 8 cents better than the analyst estimate of ($0.32). Revenue for the quarter was $55.0 million, which compares to the estimate of $46.61 million.
We are updating our financial guidance for the full year 2009 by reducing the expected range of our operating expenses to $270 million - $290 million from our previous guidance of $290 million - $320 million. The change in operating expense guidance primarily reflects continued cost savings throughout 2009 as well as more clarity into the development programs for XL184 and our PI3K assets as a result of the evolving discussions under our collaborations with Bristol-Myers Squibb (NYSE: BMY) and sanofi-aventis (NYSE: SNY). We continue to expect revenues in the range of $140 million to $170 million for the full year 2009 and our cash, cash equivalents, short-term and long-term marketable securities and restricted cash balance at the end of 2009 to exceed $200 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.49
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
